MALEE BLUE: Open Payments
NPI 1730626979 · ELKHART, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,459 in 82 payments from 19 companies in 2025. Trend: 2023 $1,384 · 2024 $1,463 · 2025 $1,459
Food & beverage: $1,376Education: $83
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 23 | $332 |
| Galderma Laboratories, L.P. | 9 | $152 |
| ABBVIE INC. | 12 | $147 |
| Novartis Pharmaceuticals Corporation | 7 | $126 |
| UCB, Inc. | 5 | $120 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| Incyte Corporation | 3 | $83 |
| GENZYME CORPORATION | 3 | $71 |
| LEO Pharma Inc. | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
Products named: TREMFYA, DUPIXENT, NEMLUVIO, Bimzelx, COSENTYX, OPZELURA, SKYRIZI, RINVOQ.
Industry payments across IN — which companies pay providers there.
